Menarini Asia-Pacific and Pharmacosmos partner to bring first-in-class oncology supportive care therapy Cosela® to Asian patients
Menarini Asia-Pacific has partnered with Pharmacosmos to distribute Cosela, a first-in-class therapy designed to protect bone marrow during chemotherapy. The agreement covers multiple Asian markets and aims to address unmet needs in oncology supportive care.
Why it matters
Expanding access to supportive oncology therapies improves treatment outcomes and quality of life for cancer patients undergoing chemotherapy.
SINGAPORE , July 21, 2026 /PRNewswire/ -- Menarini Asia-Pacific today announced an exclusive partnership with Pharmacosmos A/S to register, commercialise and distribute Cosela ® (trilaciclib) across its Asia-Pacific markets.
Chemotherapy-induced myelosuppression (CIM) is a potentially debilitating side effect that damages bone marrow, significantly impacting its hematopoietic function (or its ability to produce healthy blood cells). For patients with extensive-stage small cell lung cancer (ES-SCLC), chemotherapy remains a cornerstone of treatment, yet it is a major dose limiting complication that can disrupt treatment and compromise outcomes [1] . Cosela ® is a first-in-class prophylactic therapy [2] FDA approved to help protect bone marrow from CIM, addressing a significant unmet need in oncology supportive care for these patients.
Under the agreement, Menarini Asia-Pacific will manage all aspects of registration, reimbursement, commercialisation and distribution of Cosela ® in Australia, Hong Kong/Macau, Indonesia, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in